Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × dabrafenib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Melanoma 66 Neoplasms 23 Neoplasm Metastasis 11 Carcinoma, Non-Small-Cell Lung 10 Thyroid Neoplasms 8 Thyroid Carcinoma, Anaplastic 8 Glioma 8 Brain Neoplasms 7 Skin Neoplasms 6 Multiple Myeloma 6 Hematologic Neoplasms 5 Colorectal Neoplasms 4 Ameloblastoma 4 Thyroid Cancer, Papillary 3 Glioblastoma 3 Astrocytoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Oligodendroglioma 2 Neurocytoma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Histiocytosis, Langerhans-Cell 2 Ganglioneuroma 2 Ganglioglioma 2 Fever 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thrombocytosis 1 Solid Tumor 1

Interventions

Cyclophosphamide 133 Dexamethasone 107 Rituximab 70 fludarabine 65 Lenalidomide 59 Cytarabine 59 Gemcitabine 54 fludarabine phosphate 49 Bortezomib 48 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 42 Cisplatin 41 pomalidomide 39 Peripheral Blood Stem Cell Transplantation 38 Filgrastim 37 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 31 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Nivolumab 25 Mycophenolic Acid 25 Temozolomide 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06262919 2025-12-30

Special Drug Use-results Surveillance of Tafinlar/Mekinist

Novartis

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡